Investigating Rift Valley Fever and other infectious diseases in East and Central Africa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the burden of Rift Valley Fever (RVF) and other emerging infectious diseases in East and Central Africa, particularly in identified hotspots. The research will involve surveillance of humans, livestock, and wildlife to understand the transmission dynamics and public health threats posed by RVF during inter-epidemic periods. By collecting data on disease incidence and seroprevalence, the study seeks to inform the development of early warning systems and vaccination strategies against RVF. The study will be conducted in Kenya, Uganda, Tanzania, and the Democratic Republic of Congo.

Why it matters

Who can join: the full rules

Inclusion Criteria for health facility based study:

Category A: A sample of patients presenting to the health facility meeting this inclusion criteria will be enrolled:

• Persons ≥ 10 years of age who are malaria negative AND have undifferentiated acute fever at the time of presentation (≥ 37.5°C) or reported fever in the past 4 weeks.

Category B: A sample of patients presenting to the health facility meeting this inclusion criteria will be enrolled:

• Persons ≥ 10 years of age who are malaria positive AND have undifferentiated acute fever at the time of presentation (≥ 37.5°C) or reported fever in the past 4 weeks.

Category C: All patients at the health facility meeting these criteria will be enrolled in the study

Persons ≥ 10 years of age with:

• Unexplained bleeding with or without fever manifesting as either: Blood in vomitus, Bleeding from the gums, Bleeding from the nose, Bleeding in the eyes (red eyes), Non-menstrual genital bleeding, Bleeding from any other body site OR

• Infectious disease illness of unknown etiology requiring hospitalization. The illness should not be responding to antimalarials and/or antibiotics following 7 days of treatment

Inclusion Criteria for community cross sectional study:

Member of household 2 or more years of age.

Exclusion Criteria:

Those who do not consent or refuse written consent. If a participant is severely ill and has no next of kin to provide consent +/- witness on their behalf.

If a participant is known to have blood clotting disorders, allergies arising from injections, or if a participant has ever fainted during previous injections or blood collection

Where it's running

• Virunga Hospital & North Kivu
  Goma, North Kivu, Democratic Republic of the Congo Recruiting
• Muranga county
  Murang’a, Kenya Recruiting
• Rwekubbo health centre IV & Isingiro district
  Isingiro, Uganda Recruiting
• Kabale Regional Referral Hospital & Kabale district
  Kabale, Uganda Recruiting
• Rwekubo Health Centre IV & Rubanda district
  Rubanda, Uganda Recruiting
• South Kivu
  Bukavu, Democratic Republic of the Congo Not yet recruiting

Study contacts

• Principal investigator: M. Kariuki Njenga, PhD — Washington State University
• Study coordinator: Jeanette A Dawa, PhD
• Email: jeanette.dawa@wsu.edu
• Phone: +254750653696

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Safety and immune response evaluation of a Rift Valley Fever vaccine

  This study is testing a new vaccine for Rift Valley Fever to see if it is safe and helps people at risk build immunity against the virus.

  Recruiting Phase 2 U.S. Army Medical Research and Development Command · Fort Deterick, Maryland · NCT03609398

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.